This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cannon, C. P. Articles by Furnelli, T. Search for Related Content PubMed PubMed Citation Articles by Cannon, C. P. Articles by Furnelli, T.

ACC CLINICAL DATA STANDARDS

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes^3,3,3

A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Emergency Physicians, American Heart Association, Cardiac Society of Australia & New Zealand, National Heart Foundation of Australia, Society for Cardiac Angiography and Interventions, and the Taiwan Society of Cardiology

	Table of contents

Top Table of contents I. Introduction II. Definitions References

1. Introduction......2115
   

1. Organization of Writing Committee and Methods for Developing the ACS Clinical Data Standards......2115
   

1. Purpose of the ACS Clinical Data Standards......2116
   

1. General Considerations of the ACS Clinical Data Standards......2116
   

1. Data Elements......2116
   
2. Medication Use......2117
   
3. Risk Adjustment and Outcomes......2117
   

II. Definitions......2117

References......2129

	I. Introduction

Top Table of contents I. Introduction II. Definitions References

 
In the field of cardiology, large-scale clinical trials and registries have provided a wealth of data on hundreds of thousands of patients. This is especially true in the field of acute coronary syndromes (ACS), which range from ST-segment elevation myocardial infarction (STEMI) to non–ST-segment elevation MI (NSTEMI) to unstable angina (UA). These data have been used to define new therapies and to guide clinical care through evaluation of both the process and the quality of care and outcomes for patients with ACS.

The American College of Cardiology (ACC) recognizes the importance of using clinical data and has established a data set and launched the National Cardiovascular Data Registry (NCDR^TM), a national, voluntary registry of cardiac catheterization and percutaneous coronary intervention (PCI) procedures. Several national and international registries have adopted many of the elements and definitions contained in the ACC-NCDR^TM Cath Lab Module version 2.0 (1), thus providing the potential for more reliable comparisons across registries. Given the ACC’s recognition of the importance of standardizing a common lexicon for describing the clinical management and outcomes of patients with a variety of conditions, the ACC has expanded its role to include the development of clinical data standards.

A. Organization of writing committee and methods for developing the ACS clinical data standards.   The process undertaken in developing these clinical data standards began with the ACC Task Force on Clinical Data Standards, which identified ACS as an important area in which to standardize definitions. A writing committee was formed that included a select group of 10 physicians who have been involved in large-scale ACS clinical trials and other registries and who were recognized experts in the field. Additionally, the writing committee included members who had expertise in developing performance measures for patients with acute myocardial infarction. Finally, this group included several international members to ensure balance in the selection of data elements for the type of practice worldwide that would be reflected by the data elements and definitions recommended in these standards. Toward that end, an informal collaboration with the European Society of Cardiology (ESC) was established.

The subcommittee met several times over a period of 2 years to refine the data standards to their present form. The overriding goals were to focus on important variables needed to assess the characteristics of patients, their treatment with both medication and interventional therapies, and their outcomes. In developing the list, the writing committee balanced completeness with length and thus tried to be as concise as possible to facilitate use of these variables by others in an actual registry or trial setting. Standardized definitions for each variable are provided. For these, the writing committee again balanced greater specificity of definitions against what information can readily and reliably be obtained from medical records to make these definitions functional in the various real-world settings in which they may be used.

Writing committee members compiled and reviewed case report forms, data elements, and definitions from national or international ACS registries and previous or ongoing clinical trials to develop an initial set of data elements. Examples of these data sources include the ACC-NCDR^TM (2), the National Registry of Myocardial Infarction (NRMI) (3), the Global Registry of Acute Coronary Events (GRACE) (4), and the Monitoring Trends and Determinants of Cardiovascular Disease (MONICA) (5), as well as the Thrombolysis in Myocardial Infarction (TIMI) (6–8), and the Global Use of Streptokinase and Tissue Plasminogen Activator to Open Occluded Arteries (GUSTO) (9–11) trials.

The data elements reflected an ongoing review of the medical literature to focus on new developments. Current scientific evidence provided the basis for the selection and definition of appropriate data elements required to evaluate and manage patients with ACS. Therefore, data elements and definitions were linked whenever possible to evidence-based national guidelines. For the purposes of these clinical data standards, the writing committee chose to review and reference several ACC/American Heart Association (AHA) guidelines, including but not limited to the ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction (12) and the ACC/AHA Guidelines for the Management of Patients With Unstable Angina/Non–ST-Segment Elevation Myocardial Infarction (13). In addition, the writing committee reviewed the Management of Acute Coronary Syndromes: Acute Coronary Syndromes Without Persistent ST-segment Elevation: Recommendations of the Task Force of the European Society of Cardiology (14) and adopted the definition of myocardial infarction (MI) as recently published in an ESC/ACC consensus document on the redefinition of MI (15). On a few occasions, data elements and definitions were linked to other national guidelines, such as the National Cholesterol Education Program (NCEP III) guidelines (16).

Finally, the committee members reviewed the list of data elements bearing in mind the intent of their use. For example, some data elements can be used for risk adjustment, others can be used to construct performance measures, and several elements can be used for multiple purposes. Additional uses include patient demographics, health services research, follow-up, and outcomes analysis.

The ACC Key Elements and Data Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes was reviewed by 4 official reviewers nominated by the ACC, the ACC/AHA Task Force on Performance Measures, the NCDR Planning and Management Task Force, and 3 outside content reviewers. To increase its applicability further, the document was posted on the ACC World Wide Web site for a 30-day public comment period, and the comments were used to develop the final version. This document was approved for publication by the ACC governing body and was formally endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Emergency Physicians, American Heart Association, Cardiac Society of Australia & New Zealand, National Heart Foundation of Australia, Society for Cardiac Angiography and Interventions and the Taiwan Society of Cardiology. This document will be considered current until the Task Force on Clinical Data Standards revises or withdraws it from distribution.

The document is presently divided into 3 sections:

• Introduction: A description of the methodology of developing the ACS Clinical Data Standards and intended goals for their use.
  
• Data Elements and Definitions: A listing of key data elements and definitions.
  
• Reference Guide: A multipurpose resource that maps common data fields between ACS core data elements and other national/regional data registries, links ACS core data elements to relevant ACC/AHA guidelines, and identifies potential uses for each core element.
  

The Introduction and Data Elements and Definitions sections are published in the December issue of the Journal of the American College of Cardiology. The Reference Guide is available online at www.acc.org.

B. Purpose of the ACS clinical data standards.   There are many goals that this project hopes to fulfill by providing a list of key data elements and standardized definitions in ACS (Table 1). First, it is hoped that standardized definitions will allow better cross-comparison of results and clinical outcomes between different trials and registries. This would be particularly true for meta-analyses of trials, where differences in data collection methods and in definitions have hampered the validity of these analyses. Furthermore, the standardized definitions should also facilitate the research that comes from the trials and registries, because the key elements needed for assessment of efficacy and safety and for appropriate risk adjustment would be included in the clinical data standards.

Third, the use of standardized definitions and registry data should facilitate quality improvement. Information on these data elements that is collected as part of a quality-improvement program at a hospital, state, or national level should provide the means to assess quality of care (both the process of care and clinical outcomes) and thereby facilitate improvements.

Fourth, these data elements and definitions can be used to assess performance measures that could facilitate improvement in quality of care on a population-wide basis by identifying underuse, overuse, or misuse of therapies (19,20). For example, they could be used to compare subgroups of patients with regard to the various performance measures and to identify certain subgroups in whom medications are underused (e.g., women) (21).

Finally, the list of data elements could become the basis for a standardized charting process with the anticipation that medical charting will progressively move toward an electronic format.

C. General considerations of the ACS clinical data standards.   1. Data elements
The writing committee paid close attention to the level of detail of the information provided about certain variables, such as timing of prior cardiovascular events, timing of procedures, exact drug names vs. classes of drugs, and types of insurance. For these or any of the data elements listed, one can always decide to collect more or less information. For example, if a hospital association were compiling a registry on patient insurance status vs. cardiac procedures and outcomes, the group might use more subcategorizations than listed here. On the other hand, if a pharmaceutical company were doing a study to evaluate a new drug in UA, the type of insurance might not matter and could be omitted. A third example is a community hospital that wishes to track its use of new therapies, such as the glycoprotein IIb/IIIa inhibitors, for which as few as 10 of the listed elements might be collected on patients.

These data elements could also be expanded to include additional information, such as individual listing of all the relative contraindications to aspirin or beta-blockers, for careful measurement of performance measures, as was done in the Cooperative Cardiovascular Project (19). Expansion of the variables collected would also be expected in the setting of a randomized clinical trial of a new drug, for which additional information would be required regarding study procedures and drug therapies. Thus, depending on the intended use of the variables, one could restrict or expand the number of data elements used. In either case, the definitions provided in this document should assist in standardizing the process.

2. Medication use
Because medical therapies have such an important effect on the outcomes of patients with ACS, the proposed data elements and definitions are relatively detailed in tracking medication use. Specifically, it is proposed that data on the types of medications be collected at a minimum of 3 time points: before the acute event, the first 24 hours after the event, and at hospital discharge. In addition, antithrombotic therapies for PCI are included in this list. Furthermore, in cases in which there may be differences between drugs within a class, it is proposed that information on the exact brand be collected. One potential means of doing this efficiently in a registry is to use a coding system in which the data element (for example, for glycoprotein IIb/IIIa blockers) is not a check box of yes/no but rather a field in which a number (e.g., 0, 1, 2, or 3) is entered that represents a specific drug. In this fashion, space can be conserved on a registry form, but detailed information becomes available about the exact type of drug used. In addition, when new drugs become approved for use, they can simply be added to the definition as an extra number on the list, but no change is necessary in the data field itself on the registry form. Finally, as new classes of drugs become available, these would need to be added to the proposed list of medications.

3. Risk adjustment and outcomes
The list of data elements includes factors included in some of the major risk models, notably those developed in the GUSTO-I trial (22) and those from TIMI (23,24) and others (25). Outcomes can be adjusted for differences in patient characteristics and to allow better comparisons across hospitals, treatment strategies, and subgroups of patients. However, although the important data elements needed for risk adjustment have been included, not all of the more minor aspects needed for very detailed risk assessment or patient subset assessment have been included. Notably, relative contraindications to some medications (for example, a history of retinal bleeding for use of aspirin or a prior history of liver dysfunction for the use of statins) were not included in an effort to keep the list of elements as streamlined as possible.

Cost-effectiveness of new (and old) therapies and treatment strategies is of growing importance (26–30). This data set includes items to allow estimation of resource utilization, which will allow estimation of cardiovascular costs.

Finally, many outcomes are included in the list of data elements. These are important for the evaluation of the clinical benefits and risks of medical and interventional therapies. With regard to the definition of MI, the Committee adopted the ESC/ACC definition of MI (15) with expansion of the definition detail to match current clinical trials (6–11). The standard cutpoint of CK-MB greater than or equal to 3 times the upper limit of normal following PCI was adopted (10, 29). New data on the definition of MI following CABG was used as well (31). However, the data set recommends that all serial cardiac markers (CK-MB, CK, troponin) during the hospitalization be collected so that other thresholds could be applied. However, the data set recommends that all serial cardiac markers (CK-MB, CK, troponin) during the hospitalization be collected so that the other thresholds could be applied.

Some of the data elements listed would potentially require review by a physician (for example, final diagnosis of the admission event—UA vs. MI vs. noncardiac chest pain—or the assessment of coronary flow at cardiac catheterization) (31). However, the vast majority of data elements have simple definitions that the writing committee believes can be extracted from a standard medical chart.

In conclusion, the writing committee hopes that the attached set of data elements and definitions for patients with ACS will help facilitate research and assessment of quality of care and thereby advance the practice of medicine. 32, 33, 34

	II. Definitions

Top Table of contents I. Introduction II. Definitions References

 

ELEMENT DEFINITION Baseline Characteristics Gender Patient’s gender: male or female Date of birth Day, month, and year of the patient’s birth Race Patient’s race: 1. White 2. Black 3. Hispanic 4. Asian 5. Native American 6. Other race not llisted (Note: These categories could be used in a "check all that apply" format to identify mixed races.) Insurance Four broad types of insurance are defined as follows: 1. insurance refers to patients who are covered by government-reimbursed care. In the United States, this includes Medicare, Medicaid (including all state or federal Medicaid-type programs), and Veteran’s Administration health plans. (Consider split Medicare/Medicaid.) 2. refers to all indemnity (fee-for-service) carriers and preferred provider organizations (PPOs) (e.g., Blue Cross/Blue Shield) 3. refers to a health maintenance organization characterized by coverage that provides healthcare services for members on a prepaid "capitated" basis. 4. refers to individuals with no or limited health insurance; thus, the individual is the payer regardless of ability to pay. Only mark "None" when "self" or "none" is denoted as the first insurance in the medical record. (Note: More detailed subcategorization of these broad categories could be considered.) Prior angina History of angina before the current admission. "Angina" refers to evidence or knowledge of symptoms before this acute event described as chest pain or pressure, jaw pain, arm pain, or other equivalent discomfort suggestive of cardiac ischemia. Indicate if angina existed more than 2 weeks before admission and/or within 2 weeks before admission. Previous myocardial infarction (MI) The patient has had at least 1 documented previous MI before admission. (For a complete definition, please refer to "MI" in the "Outcomes" section.) Date should be noted. Prior congestive heart failure (CHF) History of CHF. "CHF" refers to evidence or knowledge of symptoms before this acute event described as dyspnea, fluid retention, or low cardiac output secondary to cardiac dysfunction, or the description of rales, jugular venous distension, or pulmonary edema before the current admission. Previous percutaneous coronary intervention (PCI) Previous PCI of any type (balloon angioplasty, atherectomy, stent, or other) done before the current admission. Date should be noted. Previous coronary artery bypass graft (CABG) Previous CABG done before the current admission. Date should be noted. Prior catheterization with stenosis greater than or equal to 50% Documented coronary artery disease (CAD) at coronary angiography at any time before the current admission, with at least a 50% stenosis in a major coronary artery. If the patient had a cardiac catheterization before the index event that demonstrated a stenosis of 90% and that was successfully stented to a 0% residual, this should be coded as "yes," because a stenosis of greater than or equal to 50% was documented. History of stroke Documented history of stroke or cerebrovascular accident (CVA). Typically, a patient has had a history of stroke if there was loss of neurological function caused by an ischemic event with residual symptoms at least 24 hours after onset. The year of the most recent stroke before the current admission should be noted. Type of stroke Type of stroke: 1. Hemorrhagic: A stroke with documentation on imaging (e.g., computed tomographic [CT] scan or magnetic resonance imaging [MRI] of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage) 2. Nonhemorrhagic stroke: A focal neurological deficit that results from a thrombus or embolus (and not due to hemorrhage) that appears and is still partially evident for more than 24 hours 3. Unknown type/no imaging performed: The type of stroke could not be determined by imaging or other means (lumbar puncture, neurosurgery) History of transient ischemic attack (TIA) A focal neurological deficit (usually corresponding to the territory of a single vessel) that resolves spontaneously without evidence of residual symptoms at 24 hours Peripheral arterial disease Peripheral arterial disease can include the following: 1. Claudication, either with exertion or at rest 2. Amputation for arterial vascular insufficiency 3. Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities 4. Documented aortic aneurysm 5. Positive noninvasive test (e.g., ankle brachial index less than 0.8) Diabetes History of diabetes, regardless of duration of disease, need for antidiabetic agents, or a fasting blood sugar greater than 7 mmol/l or 126 mg/dl. If yes, the type of diabetic control should be noted (check all that apply): 1. None 2. Diet: Diet treatment 3. Oral: Oral agent treatment 4. Insulin: Insulin treatment (includes any combination of insulin) Hypertension Hypertension as documented by: 1. History of hypertension diagnosed and treated with medication, diet, and/or exercise 2. Blood pressure greater than 140 mmHg systolic or 90 mmHG diastolic on at least 2 occasions 3. Current use of antihypertensive pharmacological therapy Smoking History confirming cigarette smoking in the past. Choose from the following categories: 1. Current: Smoking cigarettes within 1 month of this admission 2. Recent: Stopped smoking cigarettes between 1 month and 1 year before this admission 3. Former: Stopped smoking cigarettes greater than 1 year before this admission 4. Never: Never smoked cigarettes Dyslipidemia History of dyslipidemia diagnosed and/or treated by a physician. National Cholesterol Education Program criteria include documentation of the following: 1. Total cholesterol greater than 200 mg/dl (5.18 mmol/l); or 2. Low-density lipoprotein (LDL) greater than or equal to 130 mg/dl (3.37 mmol/l); or, 3. High-density lipoprotein (HDL) less than 40 mg/dl (1.04 mmol/l). Treatment is also initiated if LDL is greater than 100 mg/dl (2.59 mmol/l) in patients with known coronary artery disease, and this would qualify as hypercholesterolemia. Family history of CAD Any direct blood relatives (parents, siblings, children) who have had any of the following at age less than 55 years: 1. Angina 2. MI 3. Sudden cardiac death without obvious cause Chronic lung disease Documented history of chronic lung disease (i.e., chronic obstructive pulmonary disease) or currently being treated with pharmacological therapy (e.g., inhalers, theophylline, aminophylline, or steroids) and/or has a forced expiratory volume in 1 second (FEV1) less than 75%, room air pO2 less than 60%, or room air pCO2 greater than 50% Clinical Presentation Acute coronary syndrome (ACS) symptom onset: date and time • Date and time of the onset of symptoms that prompted the patient to seek medical attention • Symptom onset refers to the onset of cardiac ischemic symptoms related to this acute event, commonly appearing as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope • In the event of stuttering symptoms, ACS symptom onset is the time at which symptoms became constant in quality or intensity Presentation (to healthcare facility): date and time Date and time the patient first presented to the hospital. Type of admission The categories of type of admission are as follows: 1. Elective (i.e., scheduled more than 24 hours before hospital arrival) 2. Urgent (i.e., through the emergency department, or directly from a physician’s office) 3. Transferred from another facility Admission location The categories of location of patient at the time of admission to the hospital or observation unit are as follows: 1. Coronary or intensive care unit (CCU/ICU) 2. Step-down unit/monitored bed/cardiac ward 3. Unmonitored hospital floor 4. Observation unit/emergency department chest pain unit Means of transport The categories of the means by which the patient was transported to the facility are as follows: 1. Self/family 2. Ambulance 3. Mobile ICU 4. Air (helicopter) transfer from another facility 5. Ambulance transfer from another acute care facility Killip class Killip class of the patient at the time of hospital admission: 1. Class 1: Absence of rales over the lung fields and absence of S3 2. Class 2: Rales over 50% or less of the lung fields or the presence of an S3 3. Class 3: Rales over more than 50% of the lung fields 4. Class 4: Shock (see also Outcomes section for full definition) Heart rate Heart rate (beats per minute) should be the recording that was done closest to the time of presentation to the healthcare facility Systolic and diastolic blood pressure (at time of presentation and on discharge) Supine systolic and diastolic blood pressure (mmHg) should be the recording that was done closest to the time of presentation to the healthcare facility and on discharge Height Patient’s height in centimeters or inches Weight Patient’s weight in kilograms or pounds Angina type Category of patient’s angina type if present (choose one): I. Atypical chest pain: Pain, pressure, or discomfort in the chest, neck, or arms not clearly exertional or not otherwise consistent with pain or discomfort of myocardial ischemic origin II. Stable angina: Angina without a change in frequency or pattern for the 6 weeks before this procedure. Angina is controlled by rest and/or sublingual/oral/transcutaneous medications. III. Unstable angina (one of the following criteria is necessary): 1. Angina that occurred at rest and was prolonged, usually lasting more than 20 minutes 2. New-onset angina of at least Canadian Cardiovascular Society (CCS) classification III severity 3. Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at least CCS class III IV. MI: For a complete definition, please refer to "MI" in the "Outcomes" section. Number of episodes of angina in last 24 hours Number of distinct episodes of anginal pain that occurred in the last 24 hours before hospital admission Secondary cause of angina (yes/no) Note whether the angina was precipitated by a secondary factor such as fever, anemia, hypoxemia, tachycardia, thyrotoxicosis, or severe valvular disease, as defined by Braunwald (33) ECG Findings First 12-lead ECG: date and time Note date and time the first 12-lead ECG was performed for acute episode (whether in a prehospital setting, emergency department, or inpatient unit). Location of ECG changes The location of each type of ECG change listed below can be broken into 4 categories: 1. Inferior leads: II, III, aVF 2. Anterior leads: V1 to V4 3. Lateral leads: I, aVL, V5 to V6 4. True posterior: (relevant only for tall R waves) V1 V2 Consideration can be given to recording posterior ST-segment changes (if applicable), the maximal amount of ST-segment changes, and/or the number of leads with ST-segment changes. Type of ECG changes 1. ST-segment elevation indicates greater than or equal to 1 mm (0.1 mV) elevation in 2 or more contiguous leads 2. ST-segment depression of at least 0.5 mm (0.05 mV) in 2 or more contiguous leads (includes reciprocal changes) 3. T-wave inversion of at least 1 mm (0.1 mV) including inverted T waves that are not indicative of acute MI 4. Q waves refer to the presence of Q waves that are greater than or equal to 0.03 seconds in width and greater than or equal to 1 mm (0.1 mV) in depth in at least 2 contiguous leads Bundle-branch block (BBB) and type The presence of left or right BBB should be noted, as well as whether it is new, old, or of uncertain timing Rhythm The categories of rhythm are as follows: 1. Sinus rhythm 2. Atrial fibrillation (or flutter) 3. Paced 4. Other rhythm (e.g., ventricular tachycardia, supraventricular tachycardia) ST elevation in lead V4R If right-sided precordial leads are performed, the presence or absence of ST-segment elevation greater than or equal to 1 mm (0.1 mV) in lead V4R should be noted Follow-up ECG: new Q waves If a follow-up ECG is performed (at least 6 hours after the initial ECG, the presence or absence of new Q waves that are greater than or equal to 0.03 seconds in width, in at least 2 contiguous leads, and greater than or equal to 1 mm (0.1 mV) in depth not seen on initial ECG should be noted. Laboratory Tests Creatine kinase (CK) • Upper limit of normal The upper limit of normal of total CK as defined by individual hospital laboratory standards. The units of the CK and type of units (e.g., IU, ng/dl, kCat/l) should be noted. • All values All CK values during the hospitalization should be noted; include the units, date, and time CK-MB • Upper limit of normal The upper limit of normal of CK-MB as defined by individual hospital laboratory standards. The units of the CK-MB and type of units (e.g., IU, %, index, ng/dl, kCat/l) should be noted. • All values All MB values during the hospitalization should be noted; include the units, date, and time Troponin T or troponin I • Troponin type Indicate which type: T or I • Upper limit of normal Indicate the upper limit of normal (usually the 99th percentile of a normal population) and the units (e.g., ng/dl) • All values All troponin T or I values during the hospitalization should be noted; include units, date, and time Other labs • Total serum cholesterol level The first total serum cholesterol level and type of units should be noted • LDL First serum low density lipoprotein (LDL) and units (either calculated or direct, if measured) • HDL First serum high density lipoprotein (HDL) level and units • C-reactive protein First serum C-reactive protein level and units • Serum creatinine First creatinine level and units • Hemoglobin A1c Documented laboratory value and units for patient’s hemoglobin A1c Cardiac Procedures Stress test Indicate whether an exercise tolerance or pharmacological stress test was performed during the hospital stay. Date should be noted. • ECG alone, or either radionuclide imaging or echocardiogram Indicate if the test involved only ECG monitoring, or included either radionuclide (perfusion) imaging (e.g., thallium, Sestamibi), or echocardiography • Maximal or submaximal Maximal stress test (symptom limited) or submaximal test (e.g., modified Bruce protocol ending with stage 1 or stage 2) • Ischemia result (positive, negative, equivocal) 1. Positive: On an exercise tolerance test, the patient developed either: a. Both ischemic discomfort and ST shift greater than or equal to 1 mm (0.1 mV) (horizontal or downsloping) or b. New ST shift greater than or equal to 2 mm (0.2 mV) (horizontal or downsloping) believed to represent ischemia even in the absence of ischemic discomfort If the patient had an equivalent type of exercise test (e.g., exercise thallium or MIBI test, stress echocardiography, or dipyridamole, thallium, or adenosine radioisotope scan) that showed definite evidence of ischemia (e.g., an area of clear reversible ischemia), this should be considered a positive test. 2. Negative: No evidence of ischemia (i.e., no typical angina pain and no ST shifts). 3. Equivocal: Either: a. Typical ischemic pain but no ST shift greater than or equal to 1 mm (0.1 mV) (horizontal or downsloping) or b. ST shift of 1 mm (0.1 mV) (horizontal or downsloping) but no ischemic discomfort • Imaging testing Note presence or absence of a fixed defect indicating an old MI Ejection fraction (EF) The first EF obtained during the hospital stay. It is the percent of blood emptied from the ventricle at the end of contraction and can be obtained, in preferred order, from a left ventriculogram, radionuclide ventriculography, or echocardiogram. If only a range is estimated for EF, the midpoint of the range should be the value noted. EF test Note type of test used for EF: 1. Contrast ventriculography 2. Radionuclide ventriculography 3. Echocardiography Note also whether it was estimated or calculated. Cardiac catheterization/angiography Diagnostic cardiac catheterization/angiography performed during the hospital stay. Date should be noted. Maximum stenosis by vessel (left anterior descending coronary artery [LAD], left circumflex [LCx], right coronary artery [RCA], left main [LM], graft) Stenosis represents the percentage occlusion, from 0 to 100%, associated with the identified vessel systems. Percent stenosis at its maximal point is estimated to be the amount of reduction in the diameter of the "normal" vessel proximal to the lesion. For the denominator, take the maximum internal lumen diameter proximal and distal to the lesion. In instances where multiple lesions are present, enter the highest percentage stenosis noted. The systems of interest are as follows and should include major branch vessels of greater than 2 mm diameter: • Greatest stenosis assessed in the LAD or any major branch vessel • Greatest stenosis assessed in the LCx or any major branch vessel • Greatest stenosis assessed in the RCA or any major branch vessel • Greatest stenosis assessed in the LM • Greatest stenosis assessed in bypass graft Culprit artery Vessel considered to be responsible for the ACS. The investigator should use his/her judgment in choosing the primary vessel. In cases in which this is difficult to determine (despite correlation of ECG changes and angiographic data), the vessel supplying the largest territory of myocardium should be selected: • LAD • LCx • RCA • LM • Graft • Unknown Note: "None" should be considered if there is no apparent coronary vessel lesion that could be responsible for evidence of ischemia. Culprit artery TIMI flow TIMI grade flow in the culprit artery is defined as follows: 1. Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion 2. Grade 1 (penetration without perfusion): The contrast material passes beyond the area of obstruction but "hangs up" and fails to opacify the entire coronary bed distal to the obstruction for the duration of the cineangiographic filming sequence 3. Grade 2 (partial perfusion): The contrast material passes across the obstruction and opacifies the coronary bed distal to the obstruction. However, the rate of entry of contrast material into the vessel distal to the obstruction or its rate of clearance from the distal bed (or both) is perceptibly slower than its entry into or clearance from comparable areas not perfused by the previously occluded vessel (e.g., the opposite coronary artery or the coronary bed proximal to the obstruction) 4. Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction occurs as promptly as antegrade flow into the bed from the involved bed and is as rapid as clearance from an uninvolved bed in the same vessel or the opposite artery PCI PCI performed. Date should be noted. Time of first balloon inflation Time of the first balloon inflation or stent placement. If the exact time of first balloon inflation or initial stent (if no balloon) placement is not known, the time of the start of the procedure should be indicated. PCI status Note the status of the PCI using the following categories: I. Elective: The procedure could be deferred without increased risk of compromised cardiac outcome II. Urgent: All of the following conditions are met: A. Not elective B. Not emergency C. Procedure required during same hospitalization to minimize chance of further clinical deterioration III. Emergency: The patient’s clinical status includes any of the following: A. Ischemic dysfunction (any of the following) 1. Ongoing ischemia including rest angina despite maximal medical therapy (medical and/or intra-aortic balloon pump [IABP] 2. Acute evolving MI within 24 hours before intervention 3. Pulmonary edema requiring intubation B. Mechanical dysfunction (either of the following): 1. Shock with circulatory support 2. Shock without circulatory support IV. Salvage: The patient is undergoing CPR en route to the catheterization laboratory Number of lesions attempted Number of lesions into which an attempt was made to pass a guidewire, whether successful or not Number of stents placed Number of stents placed Number of lesions successfully dilated Number of lesions in which residual postintervention stenosis is less than 50% of the arterial luminal diameter, TIMI flow is 3, and the minimum decrease in stenosis is 20% Glycoprotein (GP) IIb/IIIa blockade Whether GP IIb/IIIa was used, and if so, when initial dose was first administered: • Before cateterization laboratory visit • Immediately preceding PCI • During PCI, but after initial balloon inflation • After catheterization laboratory visit • Contraindicated Note the exact drug used. Available drugs are abciximab, eptifibatide, tirofiban, trial-based agent (not listed above or randomized blindly between 2 agents), other. CABG CABG procedure performed during this admission. Date should be noted. IABP IABP used during this admission Pulmonary artery catheter Pulmonary artery (Swan Ganz) catheter used during this admission Temporary pacemaker Temporary pacemaker placed during this admission Permanent pacemaker Permanent pacemaker placed during this admission Ventilator Intubation and need for respiratory support on a ventilator Medications For all the medications listed below, their use at 3 time points should be noted: 1. Before hospital admission (i.e., chronic therapy) 2. During the first 24 hours after hospital admission (which does include medications given in the immediate prehospital [ambulance] setting) 3. Hospital discharge For selected medications, contraindications should be noted. Fibrinolytic therapy Fibrinolytic therapy administered. Note the exact drug used. Date and time fibrinolytic therapy initiated Date and time the intravenous (IV) fibrinolytic was initiated. If initiated by a bolus dose, note date and time the initial bolus was administered. • Fibrinolytic therapy—contraindications 1. Previous hemorrhagic stroke at any time; other strokes or cerebrovascular events within 1 year 2. Known intracranial neoplasm 3. Active or recent (within 2 to 4 weeks) internal bleeding (does not include menses) 4. Suspected aortic dissection 5. Severe uncontrolled hypertension on presentation (blood pressure 180/110 mmHg). Note: This could be an absolute contraindication in low-risk patients with MI. 6. History of prior CVA or known intracerebral pathology not covered in contraindications 7. Current use of anticoagulants in therapeutic doses (INR greater than or equal to 2); known bleeding diathesis 8. Recent trauma (within 2 to 4 weeks), including head trauma, traumatic or prolonged (greater than 10 minutes) CPR, or major surgery (less than 3 weeks) 9. Pregnancy IV nitrate Nitroglycerin was administered intravenously Nitrates (oral or topical) Oral or topical nitroglycerin was administered. Commonly prescribed agents include isosorbide dinitrate, isosorbide mononitrate, Nitro-Dur transdermal infusion system, or nitroglycerin paste. Sublingual nitroglycerin or nitroglycerin spray used on an as-needed basis only should not be noted in this category. IV beta-blockers IV beta-blockers administered. Some forms of IV beta-blockers include atenolol, metoprolol, propranolol, timolol, esmolol, and labetalol. Oral beta-blockers Oral beta-blockers administered. Some generic forms of oral beta-blockers include atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, bucindolol, bisoprolol, labetalol, and carvedilol. • Beta-blockers—contraindications 1. Allergy or history of intolerance 2. Bradycardia (heart rate less than 60 beats per minute) 3. Symptomatic acute heart failure 4. Systolic blood pressure of less than 100 mmHg 5. PR interval greater than 0.24 seconds 6. 2nd- and 3rd-degree heart block or bifascicular heart block 7. Asthma Calcium channel blockers Calcium channel blockers administered. Some generic forms of calcium channel blockers include verapamil, nifedipine, diltiazem, nicardipine, nimodipine, nisoldipine, felodipine, and amlodipine. Aspirin Aspirin administered • Aspirin—contraindications 1. True allergy to aspirin 2. Active bleeding Clopidogrel/ticlopidine Clopidogrel or ticlopidine administered Other antiplatelet agents Another antiplatelet agent, not listed above, administered (e.g., dipyridamole) GP IIb/IIIa blockers GP IIb/IIIa blockers administered. Note the exact drug used. Available drugs are abciximab, eptifibatide, tirofiban, trial-based GP IIb/IIIa blocker (i.e., not listed above or randomized blindly between 2 agents), or other. Antithrombin agents Antithrombin agent administered. Available drugs are unfractionated heparin, low-molecular-weight heparin (enoxaparin, dalteparin, nadroparin, danaparoid, hirudin, and bivalirudin), trial-based antithrombin agent (i.e., not listed above or randomized blindly between 2 agents), or other. Warfarin Warfarin (or coumarol, coumarin) administered Female hormone replacement therapy Female hormone replacement therapy administered Nicotine replacement therapy Nicotine replacement agents administered (e.g., buproprion) Antiarrhythmics Antiarrhythmic drug administered. Some common drugs are amiodarone, sotalol, quinidine, procainamide, and lidocaine. ACE inhibitors ACE inhibitors administered. Some common generic forms include captopril, enalapril, lisinopril, and ramipril. • ACE inhibitors—contraindications 1. Allergy or intolerance (e.g., cough) to ACE inhibitors 2. Moderate to severe aortic stenosis 3. Bilateral renal artery stenosis 4. History of angioedema, hives, or rash in response to ACE inhibitors 5. Hyperkalemia 6. Symptomatic hypotension 7. Severe renal dysfunction Angiotensin II receptor blocker (ARB) ARBs administered. Common forms are losartan, valsartan, and candesartan. Diuretics Diuretics administered. Some commonly prescribed agents are furosemide, ethacrynic acid, hydrochlorothiazide, spironolactone, metolazone, and bumetanide. Digitalis Digitalis administered. Some common generic forms include digoxin and digitoxin. Lipid-lowering agents Lipid-lowering agent administered. Note the type of agent: 1. Statin (HMG Co-A reductase inhibitors) 2. Fibrates 3. Nicotinic acid 4. Resin drugs 5. Other Frequently prescribed drugs are atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, cholestyramine, colestipol, probucol, and gemfibrozil. Outcomes Death Patient died during this hospitalization. Date should be noted. MI To meet the criteria as a postadmission event, an MI must be distinct from the index event at the time of admission (i.e., reinfarction for a patient who was admitted to the hospital with an MI). Date and time should be noted. MI is defined by the ESC/ACC definition below. In addition 2 different subcategorizations of MI are further specified as follows: 1. ST vs. non–ST-segment elevation MI a. ST-elevation MI vs. b. Non–ST-elevation MI vs. c. BBB/uncertain And 2. Q-wave vs. non–Q-wave MI MI (continued) a. Q wave b. Non-Q-wave MI c. BBB/Uncertain ESC/ACC DEFINITION OF MI (15) Either one of the following criteria satisfies the diagnosis for an acute, evolving, or recent MI: 1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis (see further description of *Biochemical Marker Evidence of MI below) with at least 1 of the following: a. Ischemic symptoms b. Development of pathological Q waves on the ECG (for further description, see Classification of Q-Wave vs. Non–Q-Wave MI below) c. ECG changes indicative of ischemia (ST-segment elevation or depression; for further description, see Classification of STEMI vs. Non-STEMI) d. Coronary artery intervention (e.g., coronary angioplasty) Or 2. Pathological findings of an acute MI * . The following are biochemical indicators for detecting myocardial necrosis (see below for a definition of reference control limits): 1. Troponin T or I: Maximal concentration of troponin T or I greater than the MI decision limit on at least 1 occasion during the first 24 hours after the index clinical event 2. CK-MB: a. Maximal value of CK-MB, preferably CK-MB mass, greater than upper limit of normal on 2 successive samples b. Maximal value of CK-MB greater than 2 times the upper limit of normal on 1 occasion during the first hours after the index clinical event Or 3. Total CK: In the absence of availability of a troponin or CK-MB assay, total CK greater than 2 times the upper limit of normal, or the B fraction of CK may be used, but these last 2 biomarkers are considerably less satisfactory than CK-MB : Reference values must be determined in each laboratory by studies using specific assays with appropriate quality control, as reported in peer-reviewed journals. Acceptable imprecision (coefficient of variation) at the 99th percentile for each assay should be defined as less than or equal to 10%. Each individual laboratory should confirm the range of reference values in their specific settings. : • For patients with admission MI, the CK-MB value associated with the recurrent MI must be increased by at least 50% of the previous value (i.e., a re-elevation of cardiac markers) • For patients with MI within 24 hours after PCI, the CK-MB (or CK if MB not available) must be greater than or equal to 3 times the upper limit of normal. No ECG changes or symptoms are required. • For patients with MI within 24 hours after CABG, the CK-MB (or CK if MB not available) must be greater than or equal to 5 times the upper limit of normal, and new Q waves must be present as defined above, or CK-MB value must be greater than or equal to 10 times the upper limit of normal (with or without Q waves). No symptoms are required. • For patients who die and for whom no cardiac markers were obtained, the presence of new ST-segment elevation and new chest pain would meet criteria for MI . The patient should manifest a typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis (see "Biochemical marker evidence of MI" above), and 1. . ST-segment elevation: New or presumed new ST-segment elevation at the J point in 2 or more contiguous leads with the cutoff points greater than or equal to 0.2 mV in leads V1, V2, or V3, or greater than or equal to 0.1 mV in other leads Or 2. . Either of the following (in the absence of ST elevation): a. ST-segment depression or T-wave abnormalities b. Ischemic symptoms in the presence or absence of chest discomfort. Ischemic symptoms may include: (1) unexplained nausea and vomiting or diaphoresis (2) persistent shortness of breath secondary to left ventricular failure (3) unexplained weakness, dizziness, lightheadedness, or syncope MI (continued) Or 3. : Either of the following: a. Left BBB (new or old) or paced rhythm that obscures assessment of ST elevation. (If definite new ST elevation can be identified compared with an old ECG, then STEMI should be the classification.) b. If the initial ECG findings are not available or the patient presents beyond the time of ST-segment changes (e.g., greater than 24 hours), classify as uncertain type . The patient should manifest the typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis (see "Biochemical marker evidence of MI" above), and 1. : Development of any Q wave in leads V1 through V3, or the development of a Q wave greater than or equal to 30 ms (0.03 s) in leads I, II, aVL, aVF, V4, V5, or V6. (Q-wave changes must be present in any 2 contiguous leads and be greater than or equal to 1 mm in depth.) Or 2. : The absence of new Q waves as defined above on ECGs performed at least 12 hours after the event Or 3. : Left BBB (new or old) or paced rhythm that obscures assessment of Q waves Recurrent rest angina with ECG changes Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) with associated ECG changes Recurrent rest angina without ECG changes Recurrent ischemic pain occurring at rest (and believed to be cardiac in origin) without associated ECG changes Bleeding (TIMI major, TIMI minor, or none) An episode of bleeding is defined by the TIMI criteria as: 1. Major: Overt clinical bleeding (or documented intracranial or retroperitoneal hemorrhage) associated with a drop in hemoglobin of greater than 5 g/dl (0.5 g/l) or in hematocrit of greater than 15% (absolute) Note: A patient who experiences an intracranial hemorrhage should be considered to have a major hemorrhage. 2. Minor: Overt clinical bleeding associated with a fall in hemoglobin of 3 to less than or equal to 5 g/dl (0.5 g/l) or in hematocrit of 9% to less than or equal to 15% (absolute) 3. None: No bleeding event that meets the major or minor definition Note: In calculating the fall in hemoglobin or hematocrit, a transfusion of whole blood or packed red blood cells is counted as 1 g/dl (0.1 g/l) hemoglobin or 3% absolute in hematocrit. This would be in addition to the actual fall in hemoglobin or hematocrit. Location of bleeding Categories for the location of bleeding are: • cardiac catheterization site • CABG surgical site (e.g., chest tubes, sternal wound) • other instrumented site • gastrointestinal site • other (noninstrumented) site Transfusion Transfusion of either whole blood or packed red blood cells due to a hemorrhagic event. Note the number of units transfused. Stroke A stroke or CVA with loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset or leading to death Type of stroke Indicate the type of stroke: 1. Hemorrhagic: A stroke with documentation on imaging (e.g., CT scan or MRI of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage). Evidence of hemorrhagic stroke obtained from lumbar puncture, neurosurgery, or autopsy can also confirm the diagnosis. 2. Nonhemorrhagic: A focal neurological deficit that results from a thrombus or embolus (and not due to hemorrhage) that appears and is still partially evident for more than 24 hours 3. Unknown/no imaging performed: if the type of stroke could not be determined by imaging or other means (from lumbar puncture, neurosurgery, or autopsy) Transient ischemic attack (TIA) A focal neurological deficit (usually corresponding to the territory of a single cerebral vessel) that resolves spontaneously without any evidence of residual deficit at 24 hours Thrombocytopenia Platelet count dropped to either less than 50,000/mm3 or between 50,000 and less than 100,000/mm3; the level should be noted. This platelet count should be confirmed as not being pseudothrombocytopenia (i.e., platelet clumping in citrated blood). CHF Developed evidence of new CHF after admission • None (absence of rales over the lung fields) • Mild CHF (rales over 50% or less of the lung fields). Evidence of new pulmonary vascular congestion on chest radiograph also meets the definition. • Severe CHF (rales over more than 50% of the lung fields). Evidence of pulmonary edema on chest radiograph would also meet this definition. Cardiogenic shock Experienced cardiogenic shock. Clinical criteria for cardiogenic shock are hypotension (a systolic blood pressure of less than 90 mmHg for at least 30 minutes or the need for supportive measures to maintain a systolic blood pressure of greater than or equal to 90 mmHg), end-organ hypoperfusion (cool extremities or a urine output of less than 30 ml/h, and a heart rate of greater than or equal to 60 beats per minute). The hemodynamic criteria are a cardiac index of no more than 2.2 l/min per square meter of body-surface area and a pulmonary-capillary wedge pressure of at least 15 mmHg (34). Cardiac rupture/ventricular septal defect Rupture of the ventricular myocardium, as documented by cardiac echocardiography, ventriculography, pericardiocentesis, cardiac surgery, and/or autopsy. Rupture could be of the free wall or the ventricular septum. Included in this category is frank papillary muscle rupture. Atrial arrhythmia A new episode or acute recurrence of atrial arrhythmia documented by 1 of the following: 1. Atrial fibrillation/flutter 2. Supraventricular tachycardia requiring treatment (supraventricular tachycardia that requires cardioversion, drug therapy, or is sustained for greater than 1 minute) Ventricular arrhythmia Ventricular tachycardia or ventricular fibrillation requiring cardioversion and/or intravenous antiarrhythmics High-degree atrioventricular (AV) block High-level AV block defined as third-degree AV block or second-degree AV block with bradycardia requiring pacing Date of discharge Date the patient was discharged from the acute care hospital. If the patient died in the hospital, the hospital discharge date is the date of death. Discharge destination Location the patient was discharged to upon leaving this hospital. The choices are: 1. Home 2. Nursing home or personal care residence 3. Another nonacute care or rehabilitation hospital 4. Another acute care hospital 5. Death in hospital Smoking cessation counseling Advice or a pamphlet was given or a discussion was conducted with the patient (by physician, nurse, or other personnel) regarding the importance of stopping smoking Weight management counseling Advice given or counseling conducted by a physician or nurse in patients greater than 120% of ideal weight for height. Particular emphasis for weight loss may be given for patients with hypertension, elevated triglycerides, or elevated glucose levels. Diet counseling Advice given or discussion conducted by a physician or nurse encouraging diet counseling. This can include low cholesterol foods; moderate sodium restriction; emphasis on fruits, vegetables, and low-fat dairy products; and increased consumption of omega-3 fatty acids. Exercise counseling Advice given or discussion conducted by a physician or nurse encouraging patients to engage in a minimum of 30 to 60 minutes of physical activity daily or at least 3 to 4 times weekly. Cardiac rehabilitation Advice given or discussion conducted with the patient (by physician, nurse, or other personnel) regarding the importance of joining a cardiac rehabilitation program, or an appointment made Days in ICU Total number of days the patient spent in an intensive care bed at the index hospital only, either consecutively or intermittently. To count days: 1. Find the ICU/CCU admit date/time and the date/time patient was transferred out to another unit (telemetry or unmonitored bed) 2. For every 24-hour period, count 1 day 3. For any partial day remaining, round up if greater than or equal to 12 hours and round down if less than 12 hours In the case of an in-hospital infarct in which the patient is already in an intensive care bed, record the number of days spent in ICU/CCU after the diagnosis of MI was made. Final diagnosis of the admission event The final diagnosis for the event that prompted admission: 1. is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis (e.g., positive CK-MB) and new (or presumably new if no prior ECG is available) ST-segment elevation on the admission ECG. (For a complete definition, please refer to "MI" in the "Outcomes" section.) 2. is defined as an ACS in which there is cardiac marker evidence of myocardial necrosis (e.g., positive CK-MB or troponin) without new ST-segment elevation. (For a complete definition, please refer to "MI" in the "Outcomes" section.) 3. . For a complete definition, please refer to "MI" in the "Outcomes" section. 4. is defined as angina pectoris (or equivalent type of ischemic discomfort) with any 1 of the 3 following features: a. Angina occurring at rest and prolonged, usually greater than 20 minutes b. New-onset angina of at least CCS classification III severity c. Recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at least CCS class III The patient must also not have any biochemical evidence of necrosis. a. : Patients with clinical history consistent with the diagnosis of unstable angina as described above, in whom ischemia has been confirmed by the presence of ST-segment changes on the initial ECG or in association with recurrent rest pain, by a positive stress test, or by the presence of small elevations of troponin that do not meet criteria for MI b. is present when an acute ischemic process has not been excluded as a possible cause of the presenting symptoms, or the clinical history is consistent with unstable angina but no diagnostic test (noted above) was performed to confirm the diagnosis 5. The patient has a clinical diagnosis or prior history of CAD, but after evaluation in the hospital, the episode of discomfort was not thought to have represented unstable angina 6. : Pain in the chest, neck, or arms or abdomen (or other clinical manifestation) not clearly exertional or not otherwise consistent with pain or discomfort of myocardial ischemic origin Examples: 1. If a patient was admitted with rest pain but had negative cardiac markers, then on day 3 developed recurrent pain, and it was determined that an MI had occurred, the event prompting admission should be coded as "unstable angina" here. The MI on day 3 should be recorded in the "Outcomes" section as a postadmission MI. 2. If a patient was admitted with rest pain and initial cardiac markers were negative, but the enzymes drawn over the subsequent 24 hours became positive, this is most consistent with an NSTEMI as the admission event. Follow-up Measures These elements are believed to be the most important outcomes to monitor in patients with ACS. The timing could be flexible, but the most common time points are 30 days, 6 months, and/or 1 year. Death The patient died since the previous visit/contact. This category includes all deaths regardless of cause of death. • Primary cause (cardiovascular vs. noncardiovascular) 1. Cardiovascular death indicates cause of death was sudden cardiac death, MI, unstable angina, or other CAD; vascular death (e.g., stroke, arterial embolism, pulmonary embolism, ruptured aortic aneurysm, or dissection); CHF; or cardiac arrhythmia 2. Noncardiovascular death indicates cause of death was respiratory failure, pneumonia, cancer, trauma, suicide, or any other already defined cause (e.g., liver disease or renal failure) MI Documented evidence of an MI. For a complete definition, please refer to "MI" in the "Outcomes" section. Cardiac catheterization Cardiac catheterization (with or without revascularization) procedure performed since the previous visit/contact PCI PCI performed since the previous visit/contact CABG CABG performed since the previous visit/contact Readmission Readmission to a hospital Readmission reason Reasons for admission (include all that apply): 1. MI (documented) 2. Unstable angina 3. Angina (without MI) 4. PCI 5. CABG 6. CHF (without MI) 7. Arrhythmia or conduction disturbance (without MI) 8. Other cardiovascular problem 9. Noncardiovascular problem Angina status CCS classes of angina (35): I. Ordinary physical activity (for example, walking or climbing stairs) does not cause angina; angina occurs with strenuous or rapid or prolonged exertion at work or recreation II. Slight limitation of ordinary activity (for example, angina occurs walking or stair climbing after meals, in cold, in wind, under emotional stress, or only during the few hours after awakening; walking more than 2 blocks on the level or climbing more than 1 flight of ordinary stairs at a normal pace; and in normal conditions) III. Marked limitation of ordinary activity (for example, angina occurs with walking 1 or 2 blocks on the level or climbing 1 flight of stairs in normal conditions and at a normal pace) IV. Inability to perform any physical activity without discomfort; angina syndrome may be present at rest Medication use 1. : Aspirin, clopidogrel, or ticlopidine; other (e.g., dipyridamole) 2. : Some common generic forms include captopril, enalapril, lisinopril, and ramipril 3. : Some forms of IV beta-blockers include atenolol, metoprolol, propranolol, timolol, esmolol, and labetalol. Some generic forms of oral beta-blockers include atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, bucindolol, bisoprolol, labetalol, and carvedilol. 4. : Type of agent includes statin (HMG Co-A reductase inhibitors), fibrates, nicotinic acid, resin drugs (cholestyramine). Frequently prescribed drugs are cholestyramine, colestipol, probucol, gemfibrozil, lovastatin, atorvastatin, simvastatin, fluvastatin, pravastatin, and cerivistatin. A complete listing of cardiac medications could also be collected.

	Footnotes

 
¹ This document was approved by the American College of Cardiology Board of Trustees in November 2001.

² When citing this document, the American College of Cardiology would appreciate the following citation format: Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van de Werf FJJ, Weintraub WS. ACC Key Elements and Data Definitions for Measuring the Clinical Management and Outcomes of Patients with Acute Coronrary Syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114–30.

³ This document is available on the World Wide Web site of the American College of Cardiology (www.acc.org). Reprints of this document may be purchased for $5.00 each by calling 1-800-253-4636 or by writing to the American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, Maryland 20814-1699. © 2001 by the American College of Cardiology

^* Former members of parent committee during this writing effort.

	References

Top Table of contents I. Introduction II. Definitions References

 
1. American College of Cardiology-National Cardiovascular Data Registry Version 2.0. 2001. American College of Cardiology Web site. Available at: http://www.acc.org/ncdr/cathlab.htm Accessed April 4, 2001.

2. Weintraub WS, McKay CR, Riner RN, et al. The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee. J Am Coll Cardiol. 1997;29:459–465[CrossRef][Medline]

3. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–2063[Abstract/Free Full Text]

4. Granger CB. Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. Am J Cardiol. 2000;86:4M–9M[Medline]

5. World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41:105–114[CrossRef][Medline]

6. Cannon CP, Braunwald E, McCabe CH, Antman EM. The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995;8:117–135[Medline]

7. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911–921[Abstract/Free Full Text]

8. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]

9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]

10. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med. 1996;335:775–782[Abstract/Free Full Text]

11. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Lancet. 1998;352:87–92[Medline]

12. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guideline update for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). American College of Cardiology Web site. 1999;: Available at http://www.acc.org/clinical/guidelines/nov96/1999/index.htm. Accessed January 2001

13. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970–1062[Free Full Text]

14. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000;21:1406–1432[Free Full Text]

15. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502–1513[Abstract/Free Full Text]

16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497[Free Full Text]

17. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141:190–199[CrossRef][Medline]

18. Cannon CP, Johnson EB, Cermignani M, Scirica BM, Sagarin MJ, Walls RM. Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol. 1999;22:17–20[Medline]

19. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509–1514[Abstract/Free Full Text]

20. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation. 1998;97:1150–1156[Abstract/Free Full Text]

21. Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999;84:1145–1150[CrossRef][Medline]

22. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30–day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91:1659–1668[Abstract/Free Full Text]

23. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non–ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–842[Abstract/Free Full Text]

24. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–2037[Abstract/Free Full Text]

25. Jacobs DR Jr, Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation. 1999;100:599–607[Abstract/Free Full Text]

26. Mark DB, Naylor CD, Hlatky MA, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med. 1994;331:1130–1135[Abstract/Free Full Text]

27. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424[Abstract/Free Full Text]

28. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB III. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation. 1995;92:2831–2840[Abstract/Free Full Text]

29. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation. 1996;94:629–635[Abstract/Free Full Text]

30. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation. 1998;97:1702–1707[Abstract/Free Full Text]

31. Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol. 2001;38:1070–1077[Abstract/Free Full Text]

32. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932–936[Medline]

33. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410–414[Free Full Text]

34. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625–634[Abstract/Free Full Text]

35. Campeau L. Grading of angina pectoris. Circulation. 1976;54:522[Medline]

This article has been cited by other articles:

				D. A. Morrow, S. D. Wiviott, H. D. White, J. C. Nicolau, E. Bramucci, S. A. Murphy, M. P. Bonaca, C. T. Ruff, B. M. Scirica, C. H. McCabe, et al. Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction Circulation, June 2, 2009; 119(21): 2758 - 2764. [Abstract] [Full Text] [PDF]

				The ACTIVE Investigators Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation N. Engl. J. Med., May 14, 2009; 360(20): 2066 - 2078. [Abstract] [Full Text] [PDF]

				T. Z. Potsis, C. Katsouras, and J. A. Goudevenos Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Angiology, April 1, 2009; 60(2): 148 - 158. [Abstract] [PDF]

				A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, et al. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 837 - 845. [Abstract] [Full Text] [PDF]

				S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman, and M. S. Sabatine Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1195 - 1202. [Abstract] [Full Text] [PDF]

				R. C. Hendel, M. J. Budoff, J. F. Cardella, C. E. Chambers, J. M. Dent, D. M. Fitzgerald, J. McB. Hodgson, E. Klodas, C. M. Kramer, A. E. Stillman, et al. ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SIR 2008 Key Data Elements and Definitions for Cardiac Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging) J. Am. Coll. Cardiol., January 6, 2009; 53(1): 91 - 124. [Full Text] [PDF]

				WRITING COMMITTEE MEMBERS, R. C. Hendel, M. J. Budoff, J. F. Cardella, C. E. Chambers, J. M. Dent, D. M. Fitzgerald, J. McB. Hodgson, E. Klodas, C. M. Kramer, et al. ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/ SCCT/SCMR/SIR 2008 Key Data Elements and Definitions for Cardiac Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging) Circulation, January 6, 2009; 119(1): 154 - 186. [Full Text] [PDF]

				H. M. Krumholz, J. L. Anderson, B. L. Bachelder, F. M. Fesmire, S. D. Fihn, J. M. Foody, P. M. Ho, M. N. Kosiborod, F. A. Masoudi, and B. K. Nallamothu ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine J. Am. Coll. Cardiol., December 9, 2008; 52(24): 2046 - 2099. [Full Text] [PDF]

				H. M. Krumholz, J. L. Anderson, B. L. Bachelder, F. M. Fesmire, S. D. Fihn, J. M. Foody, P. M. Ho, M. N. Kosiborod, F. A. Masoudi, and B. K. Nallamothu ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction): Developed in Collaboration With the American Academy of Family Physicians and the American College of Emergency Physicians: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine Circulation, December 9, 2008; 118(24): 2596 - 2648. [Full Text] [PDF]

				A. A. Amin, R. A. Menon, K. J. Reid, W. S. Harris, and J. A. Spertus Acute Coronary Syndrome Patients With Depression Have Low Blood Cell Membrane Omega-3 Fatty Acid Levels Psychosom Med, October 1, 2008; 70(8): 856 - 862. [Abstract] [Full Text] [PDF]

				M. Ebbing, O. Bleie, P. M. Ueland, J. E. Nordrehaug, D. W. Nilsen, S. E. Vollset, H. Refsum, E. K. Ringdal Pedersen, and O. Nygard Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial JAMA, August 20, 2008; 300(7): 795 - 804. [Abstract] [Full Text] [PDF]

				M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J., April 2, 2008; 29(8): 992 - 1000. [Abstract] [Full Text] [PDF]

				R. J.G. Peters, C. Joyner, J.-P. Bassand, R. Afzal, S. Chrolavicius, S. R. Mehta, J. Oldgren, L. Wallentin, A. Budaj, K. A. Fox, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial Eur. Heart J., February 1, 2008; 29(3): 324 - 331. [Abstract] [Full Text] [PDF]

				J. Oldgren, L. Wallentin, R. Afzal, J.-P. Bassand, A. Budaj, S. Chrolavicius, K. A.A. Fox, C. B. Granger, S. R. Mehta, P. Pais, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur. Heart J., February 1, 2008; 29(3): 315 - 323. [Abstract] [Full Text] [PDF]

				R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]

				M. J. Eskola, L. Holmvang, K. C. Nikus, S. Sclarovsky, H.-H. Tilsted, H. Huhtala, K. O. Niemela, and P. Clemmensen The electrocardiographic window of opportunity to treat vs. the different evolving stages of ST-elevation myocardial infarction: correlation with therapeutic approach, coronary anatomy, and outcome in the DANAMI-2 trial Eur. Heart J., December 2, 2007; 28(24): 2985 - 2991. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547. [Abstract] [Full Text] [PDF]

				P. de Jonge, A. Honig, J. P. van Melle, A. H. Schene, A. M.G. Kuyper, D. Tulner, A. Schins, J. Ormel, and The MIND-IT Investigators Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events Am J Psychiatry, September 1, 2007; 164(9): 1371 - 1378. [Abstract] [Full Text] [PDF]

				T. D. Henry, S. W. Sharkey, M. N. Burke, I. J. Chavez, K. J. Graham, C. R. Henry, D. L. Lips, J. D. Madison, K. M. Menssen, M. R. Mooney, et al. A Regional System to Provide Timely Access to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Circulation, August 14, 2007; 116(7): 721 - 728. [Abstract] [Full Text] [PDF]

				D. A. Katz, J. Dawson, J. R. Beshansky, P. S. Rahko, T. P. Aufderheide, M. Bogner, H. Tighouart, and H. P. Selker Does Concordance with Guideline Triage Recommendations Affect Clinical Care of Patients with Possible Acute Coronary Syndrome? Med Decis Making, August 1, 2007; 27(4): 423 - 437. [Abstract] [PDF]

				J. P. van MELLE, P. de JONGE, A. HONIG, A. H. SCHENE, A. M. G. KUYPER, H. J. G. M. CRIJNS, A. SCHINS, D. TULNER, M. P. van den BERG, and J. ORMEL Effects of antidepressant treatment following myocardial infarction The British Journal of Psychiatry, June 1, 2007; 190(6): 460 - 466. [Abstract] [Full Text] [PDF]

				D. N. Tziakas, J. C. Kaski, G. K. Chalikias, C. Romero, S. Fredericks, I. K. Tentes, A. X. Kortsaris, D. I. Hatseras, and D. W. Holt Total Cholesterol Content of Erythrocyte Membranes Is Increased in Patients With Acute Coronary Syndrome: A New Marker of Clinical Instability? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2081 - 2089. [Abstract] [Full Text] [PDF]

				S. V. Rao, J. A. Eikelboom, C. B. Granger, R. A. Harrington, R. M. Califf, and J.-P. Bassand Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., May 2, 2007; 28(10): 1193 - 1204. [Abstract] [Full Text] [PDF]

				D. A. Morrow, B. M. Scirica, E. Karwatowska-Prokopczuk, S. A. Murphy, A. Budaj, S. Varshavsky, A. A. Wolff, A. Skene, C. H. McCabe, E. Braunwald, et al. Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial JAMA, April 25, 2007; 297(16): 1775 - 1783. [Abstract] [Full Text] [PDF]

				V. Bufalino, E. D. Peterson, H. M. Krumholz, G. L. Burke, K. A. LaBresh, D. W. Jones, D. P. Faxon, A. M. Valadez, and P. Solis Nonfinancial Incentives for Quality: A Policy Statement From the American Heart Association Circulation, January 23, 2007; 115(3): 398 - 401. [Full Text] [PDF]

				N. Bhala, A. Shah, A. King, and C. Molugu Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism JAMA, January 17, 2007; 297(3): 261 - 261. [Full Text] [PDF]

				M. Kreiner, J. P. Okeson, V. Michelis, M. Lujambio, and A. Isberg Craniofacial pain as the sole symptom of cardiac ischemia: A prospective multicenter study J Am Dent Assoc, January 1, 2007; 138(1): 74 - 79. [Abstract] [Full Text] [PDF]

				J. E. Brush Jr, H. M. Krumholz, J. S. Wright, R. G. Brindis, J. G. Cacchione, J. P. Drozda Jr, J. W. Fasules, K. B. Flood, A. Garson Jr, F. A. Masoudi, et al. American College of Cardiology 2006 Principles to Guide Physician Pay-for-Performance Programs: A Report of the American College of Cardiology Work Group on Pay for Performance (A Joint Working Group of the ACC Quality Strategic Direction Committee and the ACC Advocacy Committee) J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2603 - 2609. [Full Text] [PDF]

				D. N. Tziakas, G. K. Chalikias, C. O. Antonoglou, S. Veletza, I. K. Tentes, A. X. Kortsaris, D. I. Hatseras, and J. C. Kaski Apolipoprotein E Genotype and Circulating Interleukin-10 Levels in Patients With Stable and Unstable Coronary Artery Disease J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2471 - 2481. [Abstract] [Full Text] [PDF]

				O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al. A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation Circulation, December 12, 2006; 114(24): 2636 - 2643. [Abstract] [Full Text] [PDF]

				A. E. Buxton, H. Calkins, D. J. Callans, J. P. DiMarco, J. D. Fisher, H. Leon Greene, D. E. Haines, D. L. Hayes, P. A. Heidenreich, J. M. Miller, et al. ACC/AHA/HRS 2006 Key Data Elements and Definitions for Electrophysiological Studies and Procedures: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology) J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2360 - 2396. [Full Text] [PDF]

				D. A. Katz, T. P. Aufderheide, M. Bogner, P. R. Rahko, R. L. Brown, L. M. Brown, M. E. Prekker, and H. P. Selker The Impact of Unstable Angina Guidelines in the Triage of Emergency Department Patients with Possible Acute Coronary Syndrome Med Decis Making, November 1, 2006; 26(6): 606 - 616. [Abstract] [PDF]

				N. Bhala, P. Rajasekhar, and I. Moore Fondaparinux in patients with ST-segment elevation myocardial infarction. JAMA, November 1, 2006; 296(17): 2087 - 2088. [Full Text] [PDF]

				K. P. Alexander, A. Y. Chen, L. K. Newby, J. B. Schwartz, R. F. Redberg, J. S. Hochman, M. T. Roe, W. B. Gibler, E. M. Ohman, E. D. Peterson, et al. Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative Circulation, September 26, 2006; 114(13): 1380 - 1387. [Abstract] [Full Text] [PDF]

				P. M. Ho, J. A. Spertus, F. A. Masoudi, K. J. Reid, E. D. Peterson, D. J. Magid, H. M. Krumholz, and J. S. Rumsfeld Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med, September 25, 2006; 166(17): 1842 - 1847. [Abstract] [Full Text] [PDF]

				D P Chew, D L Bhatt, A M Lincoff, K Wolski, and E J Topol Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk Heart, July 1, 2006; 92(7): 945 - 950. [Abstract] [Full Text] [PDF]

				T. Ainla, T. Marandi, R. Teesalu, A. Baburin, M. Elmet, A. Lver, M. Peeba, and J. Voitk Diagnosis and treatment of acute myocardial infarction in tertiary and secondary care hospitals in Estonia Scand J Public Health, May 1, 2006; 34(3): 327 - 331. [Abstract] [PDF]

				The Fifth Organization to Assess Strategies in Acu Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes N. Engl. J. Med., April 6, 2006; 354(14): 1464 - 1476. [Abstract] [Full Text] [PDF]

				The OASIS-6 Trial Group* Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial JAMA, April 5, 2006; 295(13): 1519 - 1530. [Abstract] [Full Text] [PDF]

				M. E. Matheny, L. Ohno-Machado, and F. S. Resnic Monitoring Device Safety in Interventional Cardiology J. Am. Med. Inform. Assoc., March 1, 2006; 13(2): 180 - 187. [Abstract] [Full Text] [PDF]

				S. V. Rao, K. O'Grady, K. S. Pieper, C. B. Granger, L. K. Newby, K. W. Mahaffey, D. J. Moliterno, A. M. Lincoff, P. W. Armstrong, F. Van de Werf, et al. A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes J. Am. Coll. Cardiol., February 21, 2006; 47(4): 809 - 816. [Abstract] [Full Text] [PDF]

				H. M. Krumholz, J. L. Anderson, N. H. Brooks, F. M. Fesmire, C. T. Lambrew, M. B. Landrum, W. D. Weaver, J. Whyte, R. O. Bonow, S. J. Bennett, et al. ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction) J. Am. Coll. Cardiol., January 3, 2006; 47(1): 236 - 265. [Full Text] [PDF]

				K. P. Alexander, A. Y. Chen, M. T. Roe, L. K. Newby, C. M. Gibson, N. M. Allen-LaPointe, C. Pollack, W. B. Gibler, E. M. Ohman, E. D. Peterson, et al. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, December 28, 2005; 294(24): 3108 - 3116. [Abstract] [Full Text] [PDF]

				P. Pascale, P. Taffe, C. Regamey, L. Kappenberger, and M. Fromer Reduced Ejection Fraction After Myocardial Infarction: Is It Sufficient To Justify Implantation of a Defibrillator? Chest, October 1, 2005; 128(4): 2626 - 2632. [Abstract] [Full Text] [PDF]

				S. D. Wiviott, E. M. Antman, K. J. Winters, G. Weerakkody, S. A. Murphy, B. D. Behounek, R. J. Carney, C. Lazzam, R. G. McKay, C. H. McCabe, et al. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial Circulation, June 28, 2005; 111(25): 3366 - 3373. [Abstract] [Full Text] [PDF]

				American College of Cardiology and the American He, J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, and S.-L. T. Normand American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1147 - 1156. [Abstract] [Full Text] [PDF]

				J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, S.-L. T. Normand, and for the American College of Cardiology and the Ame American College of Cardiology and American Heart Association Methodology for the Selection and Creation of Performance Measures for Quantifying the Quality of Cardiovascular Care Circulation, April 5, 2005; 111(13): 1703 - 1712. [Abstract] [Full Text] [PDF]

				M. R. Flynn, C. Barrett, F. G. Cosio, A. K. Gitt, L. Wallentin, P. Kearney, M. Lonergan, E. Shelley, and M. L. Simoons The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice Eur. Heart J., February 1, 2005; 26(3): 308 - 313. [Abstract] [Full Text] [PDF]

				E Di Angelantonio, M Fiorelli, D Toni, M L Sacchetti, S Lorenzano, A Falcou, M V Ciarla, M Suppa, L Bonanni, G Bertazzoni, et al. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 76 - 81. [Abstract] [Full Text] [PDF]

				D Mukherjee, E Kline-Rogers, J Fang, K Munir, and K A Eagle Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome Heart, January 1, 2005; 91(1): 23 - 26. [Abstract] [Full Text] [PDF]

				S. Garcia, M. J. Canoniero, J. A. Chirinos, E. de Marchena, T. Salerno, and A. Ferreira Development of a Score to Predict the Need for Coronary Artery Bypass Graft Surgery in Patients With Non-ST Segment Elevation Acute Coronary Syndromes Ann. Thorac. Surg., December 1, 2004; 78(6): 2022 - 2026. [Abstract] [Full Text] [PDF]

				C. M. Gibson, R. L. Dumaine, E. V. Gelfand, S. A. Murphy, D. A. Morrow, S. D. Wiviott, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials Eur. Heart J., November 2, 2004; 25(22): 1998 - 2005. [Abstract] [Full Text] [PDF]

				B. D. MacNeill, I.-K. Jang, B. E. Bouma, N. Iftimia, M. Takano, H. Yabushita, M. Shishkov, C. R. Kauffman, S. L. Houser, H.T. Aretz, et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease J. Am. Coll. Cardiol., September 1, 2004; 44(5): 972 - 979. [Abstract] [Full Text] [PDF]

				C. P. Cannon, E. Braunwald, C. H. McCabe, D. J. Rader, J. L. Rouleau, R. Belder, S. V. Joyal, K. A. Hill, M. A. Pfeffer, A. M. Skene, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes N. Engl. J. Med., April 8, 2004; 350(15): 1495 - 1504. [Abstract] [Full Text] [PDF]

				D. Mukherjee, J. Fang, S. Chetcuti, M. Moscucci, E. Kline-Rogers, and K. A. Eagle Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes Circulation, February 17, 2004; 109(6): 745 - 749. [Abstract] [Full Text] [PDF]

				M. Flynn, S. Reddy, W. Shepherd, C. Holmes, D. Armstrong, C. Lunn, K. Khan, and S. Kendall Fast-tracking revisited: routine cardiac surgical patients need minimal intensive care Eur. J. Cardiothorac. Surg., January 1, 2004; 25(1): 116 - 122. [Abstract] [Full Text] [PDF]

				R. V. Freeman, R. H. Mehta, W. Al Badr, J. V. Cooper, E. Kline-Rogers, and K. A. Eagle Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors J. Am. Coll. Cardiol., March 5, 2003; 41(5): 718 - 724. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cannon, C. P. Articles by Furnelli, T. Search for Related Content PubMed PubMed Citation Articles by Cannon, C. P. Articles by Furnelli, T.